DNA sequences from staphylococcus aureus bacteriophage 77 that encode anti-microbial polypeptides
The disclosure concerns particular bacteriophage open reading frame, and portions and products of those open reading frames which have antimicrobial activity. Methods of using such products are also described.
If you were to search for DNA sequences from staphylococcus aureus bacteriophage 77 that encode anti-microbial polypeptides using relaxed search criteria, these patents would come up:
What is claimed is:
1. An isolated, purified, or enriched nucleic acid sequence at least 90 nucleotides in length, wherein said sequence is at least 95% identical to a Staphylococcus aureusbacteriophage 77 open reading frame (ORF) selected from the group consisting of ORF 17 (SEQ ID NO: 4), ORF 19 (SEQ ID NO: 5), ORF 43 (SEQ ID NO: 6), ORF 102 (SEQ ID NO: 7), ORF 104 (SEQ ID NO: 8), and ORF 182 (SEQ ID NO: 9).
2. A recombinant expression vector comprising a nucleic acid sequence at least 90 nucleotides in length, wherein said sequence is at least 95% identical to a Staphylococcus aureus bacteriophage 77 open reading frame (ORF) selected from thegroup consisting of ORF 17 (SEQ ID NO: 4), ORF 19 (SEQ ID NO: 5), ORF 43 (SEQ ID NO: 6), ORF 102 (SEQ ID NO: 7), ORF 104 (SEQ ID NO: 8), and ORF 182 (SEQ ID NO: 9).
3. A cell comprising an expression vector, wherein said vector comprises a nucleic acid sequence at least 90 nucleotides in length, wherein said sequence is at least 95% identical to a Staphylococcus aureus bacteriophage 77 open reading frame(ORF) selected from the group consisting or ORF 17 (SEQ ID NO: 4), ORF 19 (SEQ ID NO: 5), ORF 43 (SEQ ID NO: 6), ORF 102 (SEQ ID NO: 7), ORF 104 (SEQ ID NO: 8), and ORF 182 (SEQ ID NO: 9).
4. The nucleic acid sequence of claim 1, wherein said open reading frame is open reading frame 17 (SEQ ID NO. 4).
5. The nucleic acid sequence of claim 1, wherein said open reading frame is open reading frame 19 (SEQ ID NO. 5).
6. The nucleic acid sequence of claim 1, wherein said open reading frame is open reading frame 43 (SEQ ID NO. 6).
7. The nucleic acid sequence of claim 1, wherein said open reading frame is open reading frame 102 (SEQ ID NO. 7).
8. The nucleic acid sequence of claim 1, wherein said open reading frame is open reading frame 104 (SEQ ID NO. 8).
9. The nucleic acid sequence of claim 1, wherein said open reading frame is open reading frame 182 (SEQ ID NO. 9).
10. The nucleic acid sequence of claim 1, wherein said nucleic acid is at least 120 nucleotides in length.
11. The nucleic acid sequence of claim 1, wherein said nucleic acid sequence is transcriptionally linked with regulatory sequences enabling induction of expression of said sequence.
12. The vector of claim 2, wherein expression of said nucleic acid sequence is inducible.
13. The vector of claim 12, wherein said expression is inducible using arsenite inducible operator and promoter.
14. The cell of claim 3, wherein expression from said nucleic acid sequence in said expression vector is inducible.
15. The cell of claim 14, wherein said expression is inducible using arsenite inducible operator and promoter.
16. A method for preparing a polypeptide encoded by nucleic acid sequence which is at least 90 nucleotides in length, wherein said sequence is at least 95% identical to a Staphylococcus aureus bacteriophage 77 open reading frame (ORF) selectedfrom the group consisting of ORF 17 (SEQ ID NO: 4), ORF 19 (SEQ ID NO: 5), ORF 43 (SEQ ID NO: 6), ORF 102 (SEQ ID NO: 7), ORF 104 (SEQ ID NO: 8), and ORF 182 (SEQ ID NO: 9), said method comprising culturing a cell according to claim 13 under conditionspromoting expression of said polypeptide and recovering the polypeptide so expressed.
Patent number:
6982153
View patent at USPTO
Filing date:
September 28, 1999
Issue date:
January 3, 2006
Inventors:
Philippe Gros (St. Lambert, CA)
Jerry Pelletier (Baie-D'Urfe, CA)
Michael DuBow (Montreal, CA)
Assignee:
Targanta Therapeutics, Inc. (St. Laurent, CA)
Primary Examiner:
Robert A. Wax
Attorney, Agent or Firm:
Sughrue Mion, PLLC
Current U.S. Classification: 435/252.3 435/254.11 435/320.1 435/69.1 536/23.72
